Solventum (NYSE:SOLV) announced a strategic partnership with SprintRay to deliver disruptive 3D printing for dental ...
Solventum (NYSE: SOLV), the leader in dental composites and restorative dentistry, today announced a strategic partnership ...
StockStory.org on MSN10d
Solventum (SOLV): Buy, Sell, or Hold Post Q4 Earnings?Solventum has been treading water for the past six months, recording a small return of 2.6% while holding steady at $74.01.
StockStory.org on MSN7d
Q4 Earnings Outperformers: Solventum (NYSE:SOLV) And The Rest Of The Surgical Equipment & Consumables - Diversified StocksThe end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...
This partnership aligns with Solventum’s commitment to growth and digital innovation, following their recognition with seven Dental Advisor awards in 2024 and the introduction of four new products, ...
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
aims to provide a diversified portfolio of products and solutions across multiple healthcare needs to hedge against market downturns. Key success factors for Solventum include its ability to ...
Solventum and SprintRay enter dental 3D printing partnership - to produce chairside 3D printed crowns, inlays, onlays, and ...
"Together, we can make a significant impact in restorative dentistry by building exceptional products for same-visit treatment," said SprintRay CEO Amir Mansouri. "Our partnership with Solventum ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback